Jefferies Financial Group Inc. Takes $399,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Jefferies Financial Group Inc. acquired a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 30,601 shares of the company's stock, valued at approximately $399,000. Jefferies Financial Group Inc. owned 0.06% of Bicara Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in shares of Bicara Therapeutics by 1,457.9% during the 4th quarter. Vanguard Group Inc. now owns 1,090,528 shares of the company's stock worth $18,997,000 after purchasing an additional 1,020,528 shares during the last quarter. Corebridge Financial Inc. purchased a new stake in Bicara Therapeutics during the 4th quarter worth approximately $167,000. JPMorgan Chase & Co. raised its holdings in shares of Bicara Therapeutics by 8,768.5% during the fourth quarter. JPMorgan Chase & Co. now owns 64,740 shares of the company's stock valued at $1,128,000 after acquiring an additional 64,010 shares during the last quarter. Norges Bank purchased a new position in shares of Bicara Therapeutics in the fourth quarter valued at approximately $1,219,000. Finally, Alliancebernstein L.P. boosted its stake in shares of Bicara Therapeutics by 16.0% in the fourth quarter. Alliancebernstein L.P. now owns 821,264 shares of the company's stock worth $14,306,000 after acquiring an additional 113,261 shares during the last quarter.

Analysts Set New Price Targets

Several research analysts recently commented on BCAX shares. HC Wainwright reduced their price objective on Bicara Therapeutics from $44.00 to $41.00 and set a "buy" rating for the company in a research note on Friday, May 16th. Wells Fargo & Company raised shares of Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 target price for the company in a report on Friday, May 23rd. Wedbush reiterated an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Friday, May 23rd. Finally, Wall Street Zen lowered shares of Bicara Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Bicara Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $31.86.

Bicara Therapeutics Stock Performance

Shares of BCAX stock remained flat at $10.20 on Friday. 194,114 shares of the stock traded hands, compared to its average volume of 616,161. Bicara Therapeutics Inc. has a 1 year low of $7.80 and a 1 year high of $28.09. The company's fifty day moving average price is $10.43 and its 200-day moving average price is $11.98.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.28). As a group, equities research analysts predict that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Bicara Therapeutics Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.